دورية أكاديمية
[Molecular pathology of lung cancer in routine diagnostic practice: 2017 update].
| العنوان: | [Molecular pathology of lung cancer in routine diagnostic practice: 2017 update]. |
|---|---|
| عنوان ترانسليتريتد: | Molekulární patologie plicních karcinomů pro rutinní praxi - update 2017. |
| المؤلفون: | Matěj R, Rohan Z, Němejcová K, Dundr P |
| المصدر: | Ceskoslovenska patologie [Cesk Patol] Winter 2017; Vol. 53 (4), pp. 159-166. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | Czech |
| بيانات الدورية: | Publisher: Ceska Lekarska Spolecnost Country of Publication: Czech Republic NLM ID: 0050734 Publication Model: Print Cited Medium: Print ISSN: 1210-7875 (Print) Linking ISSN: 12107875 NLM ISO Abbreviation: Cesk Patol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Praha : Ceska Lekarska Spolecnost Original Publication: Praha : Státní zdravotnické nakladatelství, 1965- |
| مواضيع طبية MeSH: | Adenocarcinoma*/diagnosis , Adenocarcinoma*/genetics , Adenocarcinoma*/therapy , Carcinoma, Non-Small-Cell Lung*/diagnosis , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/therapy , Lung Neoplasms*/diagnosis , Lung Neoplasms*/genetics , Lung Neoplasms*/therapy, Humans ; Mutation ; Pathology, Molecular ; Protein-Tyrosine Kinases ; Proto-Oncogene Proteins |
| مستخلص: | The group of non-small cell lung carcinomas includes tumors that are variable at the clinical, histopathological and molecular levels. Advances in the understanding of molecular pathology of lung adenocarcinomas in particular led to changes in their histopathological classification and treatment. Patients diagnosed with lung adenocarcinoma harboring specific mutations benefit from the administration of specific targeted therapy. Analysis of EGFR gene mutations and ALK rearrangement in lung adenocarcinomas are already routinely performed and are closely related to the indication for the administration of tyrosinkinase inhibitors. Besides EGFR mutations and ALK rearrangement there are also available other potential markers for analyzing, e.g. b-raf - BRAF, ROS1. Moreover, immunotherapy needs standardization of detection of crucial molecules, namely PD-L1. The aim of this review is to summarize the role of the most relevant molecules that could also serve as the therapeutic target for practicing pathologists. |
| فهرسة مساهمة: | Keywords: NSCLC - lung adenocarcinoma - EGFR - ALK - BRAF - KRAS - RET - MET - PD-L1 - ROS1. |
| المشرفين على المادة: | 0 (Proto-Oncogene Proteins) EC 2.7.10.1 (Protein-Tyrosine Kinases) |
| تواريخ الأحداث: | Date Created: 20171212 Date Completed: 20190401 Latest Revision: 20190401 |
| رمز التحديث: | 20240628 |
| PMID: | 29227119 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!